Alkermes reports alixorexton narcolepsy trial data

• Alkermes reported sustained improvements from alixorexton in a long-term extension study for narcolepsy patients.
• The investigational oral OX2R agonist showed improvements in wakefulness, sleepiness, cognition and fatigue measures after 24 weeks.
• Alkermes said alixorexton remained generally safe and well tolerated across tested dose groups.

Alkermes (NASDAQ:ALKS) reported interim results from its ongoing long-term extension study of alixorexton in adults with narcolepsy type 1 and narcolepsy type 2, showing sustained improvements in wakefulness, sleepiness and patient-reported outcomes after 24 weeks.

The results followed the Phase 2 Vibrance-1 and Vibrance-2 studies, where participants continued treatment with alixorexton for up to approximately nine months after receiving their first dose during the randomized double-blind trials.

In narcolepsy type 1 participants, all alixorexton dose groups achieved average Maintenance of Wakefulness Test results within the normal wakefulness range, with mean sleep latency of approximately 29 minutes at week 24, while Epworth Sleepiness Scale scores remained within the normal range.

Alkermes reported that alixorexton was generally safe and well tolerated across all tested doses, with detailed safety data collected through the May 12, 2026 cutoff.

Alixorexton is an investigational oral selective orexin 2 receptor agonist being developed for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.

Alkermes continues evaluating alixorexton through ongoing Phase 2 and Phase 3 studies, with the long-term extension study remaining open for eligible participants completing related clinical trials.